Do analysts recommend PHIO or CELU?

Phio Pharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 1,398.13%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Phio Pharmaceuticals is more favorable than Celularity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PHIO or HOWL more profitable?

Phio Pharmaceuticals' return on equity of -87.41% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -87.41% -79.76% Werewolf Therapeutics N/A -166.99% -59.88%

Does the media prefer PHIO or HOWL?

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 4 mentions for Phio Pharmaceuticals and 3 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.20 beat Phio Pharmaceuticals' score of 0.80 indicating that Werewolf Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phio Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, PHIO or TVGN?

Tevogen Bio is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phio Pharmaceuticals N/A N/A -$8.70M -$1.29 N/A Tevogen Bio N/A N/A -$26.27M -$4.63 N/A

Is PHIO or TVGN more profitable?

Tevogen Bio's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -87.41% -79.76% Tevogen Bio N/A N/A -468.32%

Does the media favor PHIO or TVGN?

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 4 mentions for Phio Pharmaceuticals and 3 mentions for Tevogen Bio. Phio Pharmaceuticals' average media sentiment score of 0.80 beat Tevogen Bio's score of 0.45 indicating that Phio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phio Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PHIO or MGX?

In the previous week, Phio Pharmaceuticals had 2 more articles in the media than Metagenomi. MarketBeat recorded 4 mentions for Phio Pharmaceuticals and 2 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.91 beat Phio Pharmaceuticals' score of 0.80 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phio Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PHIO or IZTC?

Phio Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 1,398.13%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Phio Pharmaceuticals is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, PHIO or IZTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phio Pharmaceuticals N/A N/A -$8.70M -$1.29 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is PHIO or IZTC more profitable?

Invizyne Technologies' return on equity of 0.00% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -87.41% -79.76% Invizyne Technologies N/A N/A N/A

Phio Pharmaceuticals (PHIO) Competitors

$0.95 +0.02 (+1.62%)

Closing price 03:59 PM Eastern

Extended Trading

$0.93 -0.02 (-1.96%)

As of 04:27 PM Eastern

Compare

PHIO vs. CELU, HOWL, TVGN, MGX, and IZTC

Should you buy Phio Pharmaceuticals stock or one of its competitors? Phio Pharmaceuticals's main competitors and comparable companies include Celularity (CELU), Werewolf Therapeutics (HOWL), Tevogen Bio (TVGN), Metagenomi (MGX), and Invizyne Technologies (IZTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Phio Pharmaceuticals compare to Celularity?

Phio Pharmaceuticals (NASDAQ:PHIO) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 3.5% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 17.3% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Phio Pharmaceuticals has a net margin of 0.00% compared to Celularity's net margin of -374.87%. Celularity's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
Celularity	-374.87%	N/A	-64.45%

Phio Pharmaceuticals has higher earnings, but lower revenue than Celularity. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
Celularity	$26.55M	1.74	-$91.72M	-$2.73	N/A

Phio Pharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 1,398.13%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Phio Pharmaceuticals is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Phio Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Celularity has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

In the previous week, Phio Pharmaceuticals had 2 more articles in the media than Celularity. MarketBeat recorded 4 mentions for Phio Pharmaceuticals and 2 mentions for Celularity. Celularity's average media sentiment score of 0.93 beat Phio Pharmaceuticals' score of 0.80 indicating that Celularity is being referred to more favorably in the news media.

Company	Overall Sentiment
Phio Pharmaceuticals	Positive
Celularity	Positive

Summary

Phio Pharmaceuticals beats Celularity on 9 of the 14 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Werewolf Therapeutics?

Phio Pharmaceuticals (NASDAQ:PHIO) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Phio Pharmaceuticals' return on equity of -87.41% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
Werewolf Therapeutics	N/A	-166.99%	-59.88%

Phio Pharmaceuticals presently has a consensus target price of $14.00, indicating a potential upside of 1,398.13%. Werewolf Therapeutics has a consensus target price of $4.00, indicating a potential upside of 303.59%. Given Phio Pharmaceuticals' higher possible upside, equities research analysts plainly believe Phio Pharmaceuticals is more favorable than Werewolf Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Werewolf Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 4 mentions for Phio Pharmaceuticals and 3 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.20 beat Phio Pharmaceuticals' score of 0.80 indicating that Werewolf Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phio Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phio Pharmaceuticals has higher earnings, but lower revenue than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
Werewolf Therapeutics	$1.88M	25.62	-$60.82M	-$0.76	N/A

Phio Pharmaceuticals has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 3.5% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Werewolf Therapeutics beats Phio Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Tevogen Bio?

Phio Pharmaceuticals (NASDAQ:PHIO) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Phio Pharmaceuticals has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

57.3% of Phio Pharmaceuticals shares are held by institutional investors. 3.5% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 65.6% of Tevogen Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 4 mentions for Phio Pharmaceuticals and 3 mentions for Tevogen Bio. Phio Pharmaceuticals' average media sentiment score of 0.80 beat Tevogen Bio's score of 0.45 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phio Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phio Pharmaceuticals presently has a consensus price target of $14.00, indicating a potential upside of 1,398.13%. Tevogen Bio has a consensus price target of $100.00, indicating a potential upside of 1,306.47%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Tevogen Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Tevogen Bio's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
Tevogen Bio	N/A	N/A	-468.32%

Tevogen Bio is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A

Summary

Phio Pharmaceuticals beats Tevogen Bio on 10 of the 12 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Metagenomi?

Phio Pharmaceuticals (NASDAQ:PHIO) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

57.3% of Phio Pharmaceuticals shares are held by institutional investors. 3.5% of Phio Pharmaceuticals shares are held by insiders. Comparatively, 12.5% of Metagenomi shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Phio Pharmaceuticals has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
Metagenomi	-384.61%	-63.65%	-44.52%

Phio Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Phio Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 1,398.13%. Metagenomi has a consensus price target of $6.00, suggesting a potential upside of 554.09%. Given Phio Pharmaceuticals' higher probable upside, research analysts plainly believe Phio Pharmaceuticals is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Phio Pharmaceuticals has higher earnings, but lower revenue than Metagenomi. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
Metagenomi	$25.21M	1.37	-$87.87M	-$2.49	N/A

In the previous week, Phio Pharmaceuticals had 2 more articles in the media than Metagenomi. MarketBeat recorded 4 mentions for Phio Pharmaceuticals and 2 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.91 beat Phio Pharmaceuticals' score of 0.80 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phio Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Metagenomi beats Phio Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Invizyne Technologies?

Phio Pharmaceuticals (NASDAQ:PHIO) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

57.3% of Phio Pharmaceuticals shares are held by institutional investors. 3.5% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Phio Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 1,398.13%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Phio Pharmaceuticals is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Invizyne Technologies' return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
Invizyne Technologies	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

In the previous week, Phio Pharmaceuticals had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for Phio Pharmaceuticals and 0 mentions for Invizyne Technologies. Phio Pharmaceuticals' average media sentiment score of 0.80 beat Invizyne Technologies' score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phio Pharmaceuticals	Positive
Invizyne Technologies	Neutral

Summary

Phio Pharmaceuticals beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

Get Phio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHIO vs. The Competition

Export

Metric	Phio Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.03M	$3.90B	$7.28B	$12.92B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-0.74	12.49	275.28	25.28
Price / Sales	N/A	1,151.22	562.38	78.55
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.51	16.55	10.52	5.92
Net Income	-$8.70M	-$22.69M	$3.50B	$381.04M
7 Day Performance	-4.99%	-6.66%	-4.32%	-4.41%
1 Month Performance	-7.81%	-14.41%	-8.66%	-7.30%
1 Year Performance	-57.23%	5.91%	1.94%	-5.04%

Phio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHIO Phio Pharmaceuticals	4.5064 of 5 stars	$0.95 +1.6%	$14.00 +1,374.3%	-57.1%	$11.03M	N/A	N/A	6	Short Interest Decrease Gap Down
CELU Celularity	0.78 of 5 stars	$1.56 -8.8%	N/A	-30.4%	$45.16M	$26.55M	N/A	115	Short Interest Decrease
HOWL Werewolf Therapeutics	2.6529 of 5 stars	$0.92 -0.9%	$4.00 +333.8%	-39.2%	$44.81M	$1.88M	N/A	14	News Coverage Positive News
TVGN Tevogen Bio	1.4407 of 5 stars	$6.59 -0.2%	$100.00 +1,418.6%	-80.1%	$42.88M	N/A	N/A	18	Gap Down
MGX Metagenomi	4.1217 of 5 stars	$1.03 -1.1%	$6.00 +483.1%	-67.8%	$38.87M	$13.56M	N/A	113	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHIO) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. CELU, HOWL, TVGN, MGX, and IZTC

How does Phio Pharmaceuticals compare to Celularity?

Summary

How does Phio Pharmaceuticals compare to Werewolf Therapeutics?

Summary

How does Phio Pharmaceuticals compare to Tevogen Bio?

Summary

How does Phio Pharmaceuticals compare to Metagenomi?

Summary

How does Phio Pharmaceuticals compare to Invizyne Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. CELU, HOWL, TVGN, MGX, and IZTC

How does Phio Pharmaceuticals compare to Celularity?

Do insiders and institutionals have more ownership in PHIO or CELU?

Is PHIO or CELU more profitable?

Which has higher earnings and valuation, PHIO or CELU?

Do analysts recommend PHIO or CELU?

Which has more risk and volatility, PHIO or CELU?

Does the media prefer PHIO or CELU?

Summary

How does Phio Pharmaceuticals compare to Werewolf Therapeutics?

Is PHIO or HOWL more profitable?

Do analysts rate PHIO or HOWL?

Does the media prefer PHIO or HOWL?

Which has preferable earnings and valuation, PHIO or HOWL?

Which has more volatility and risk, PHIO or HOWL?

Do institutionals and insiders believe in PHIO or HOWL?

Summary

How does Phio Pharmaceuticals compare to Tevogen Bio?

Which has more risk and volatility, PHIO or TVGN?

Do institutionals and insiders hold more shares of PHIO or TVGN?

Does the media favor PHIO or TVGN?

Do analysts recommend PHIO or TVGN?

Is PHIO or TVGN more profitable?

Which has higher valuation and earnings, PHIO or TVGN?

Summary

How does Phio Pharmaceuticals compare to Metagenomi?

Do institutionals & insiders hold more shares of PHIO or MGX?

Is PHIO or MGX more profitable?

Which has more volatility & risk, PHIO or MGX?

Do analysts rate PHIO or MGX?

Which has stronger valuation & earnings, PHIO or MGX?

Does the media prefer PHIO or MGX?

Summary

How does Phio Pharmaceuticals compare to Invizyne Technologies?

Do institutionals and insiders hold more shares of PHIO or IZTC?

Do analysts rate PHIO or IZTC?

Is PHIO or IZTC more profitable?

Which has higher valuation & earnings, PHIO or IZTC?

Does the media refer more to PHIO or IZTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools